Drug-induced lupus erythematosus historical perspective

Drug-induced lupus erythematosus Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Drug-induced lupus erythematosus from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Drug-induced lupus erythematosus historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Drug-induced lupus erythematosus historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Drug-induced lupus erythematosus historical perspective
CDC on Drug-induced lupus erythematosus historical perspective
Drug-induced lupus erythematosus historical perspective in the news
Blogs on Drug-induced lupus erythematosus historical perspective
Directions to Hospitals Treating Drug-induced lupus erythematosus
Risk calculators and risk factors for Drug-induced lupus erythematosus historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

Hydralazine was the first agent to be associated with the development of lupus-like symptoms in 1954. Since then, more than 100 drugs have been identified as the cause of drug-induced lupus, with the list expanding with the development of newer biologic agents each year.